Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 12/20 | 0.47 |
| ▸ | MMP1 | P03956 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 6/20 | 0.47 |
| ▸ | MMP9 | P14780 | 6/20 | 0.47 |
| ▸ | MMP8 | P22894 | 6/20 | 0.47 |
| ▸ | MMP13 | P45452 | 6/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618140 | 0.92 | CA1 (0.47) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1618330 | 0.87 | CA1 (0.37) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL13455184 | 0.86 | CA2 (0.55) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1618620 | 0.85 | CA2 (0.48) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1618321 | 0.85 | CA1 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL27241389 | 0.83 | CA2 (0.47) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1618772 | 0.80 | CA1 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL16594047 | 0.79 | CA2 (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL27241359 | 0.78 | CA2 (0.55) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1618550 | 0.77 | CA1 (0.41) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964541-B2 | a mixture of hydrocarbon solvents, fatty acids, ammonium and/or phosphonium compounds, used as lapping oils for finishing recorders | TOKUYAMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7923142-B2 | Onium salt, electrolyte for nonaqueous cell containing the novel onium salt for nonaqueous cell and method for optimizing negative electrode using electrolyte containing onium salt | TOKUYAMA CORPORATION (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7846576-B2 | Onium salt, electrolyte for non-aqueous cell containing the novel onium salt for nonaqueous cell, and method for optimizing negative electrode using elecrolyte containing onium salt | TOKUYAMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080176779-A1 | Lubricant Composition for Polishing a Magnetic Head with Fixed Abrasive Grains | TOKUYAMA CORPORATION (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080039634-A1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT | TOKUYAMA CORPORATION | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039634-A1 | NOVEL ONIUM SALT, ELECTROLYTE FOR NONAQUEOUS CELL CONTAINING THE NOVEL ONIUM SALT FOR NONAQUEOUS CELL AND METHOD FOR OPTIMIZING NEGATIVE ELECTRODE USING ELECTROLYTE CONTAINING ONIUM SALT | CA2, SLC9A2, HCN3 | CA2 1/4885CA1 28/4885MMP1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.